The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Trastuzumab monotherapy is not associated with significant cardiotoxicity but, when administered concurrently with adjuvant anthracyclines or following neo-adjuvant anthracycline therapies, dilated cardiomyopathy/congestive heart failure may develop [195,196].”
BackgroundUntangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 2×
“Binding of Grb2-Sos to ErbB receptors positions Sos at the plasma membrane where it activates the membrane-bound small G protein Ras by enhancing exchange of GTP for Ras-bound GDP [51,60].”
BackgroundNagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 1×
“attenuation of PtdIns (3,4,5)P3 signalling by activation of the PTEN lipid phosphatase and resultant attenuation of PI3K/PKB(Akt) signalling [189]] or reduced expression of the anti-apoptotic Bcl-2 family proteins [190].”
BackgroundAn allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650 · cited 2×
“In the monomeric state, the PTK sub-domain exists as an inactive autoinhibited conformation [12,15,16,19].”
BackgroundSynthesis and Function of 3-Phosphorylated Inositol Lipids
Vanhaesebroeck, B., Leevers, S. J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P. C., Woscholski, R., Parker, P. J., & Waterfield, M. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.535 · Cited by 1,535 · cited 1×
“The Class 1A PI3K lipid kinases consist of a dimer of an 110 kDa catalytic subunit (of which there are three — p110α, p110β and p110δ) and an 85 or 55 kDa regulatory subunit (p85α, p85β or p55γ) [63,64].”
BackgroundGSK3 takes centre stage more than 20 years after its discovery
FRAME, S., & COHEN, P. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3590001 · Cited by 1,433
The discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227 · cited 3×
“Knowledge has subsequently expanded enormously and the historical perspective has been fully described recently [1,2].”
BackgroundStrain-Dependent Epithelial Defects in Mice Lacking the EGF Receptor
Sibilia, M., & Wagner, E. F. (1995) · Science · doi:10.1126/science.7618085 · Cited by 1,002
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873 · cited 1×
“Pertuzumab sterically disrupts ErbB2 heterodimerisation with the EGFR or ErbB3 by binding to residues close to the ErbB2 dimerisation arm [20,202].”
BackgroundBhaskar, P. T., & Hay, N. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.03.020 · Cited by 798
Phosphotyrosine interactome of the ErbB‐receptor kinase family
Schulze, W. X., Deng, L., & Mann, M. (2005) · Molecular Systems Biology · doi:10.1038/msb4100012 · Cited by 753
Herceptin acts as an anti-angiogenic cocktail
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K. (2002) · Nature · doi:10.1038/416279b · Cited by 623
Cooley, S., Burns, L. J., Repka, T., & Miller, J. S. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00089-2 · Cited by 213 · cited 1×
“For optimal efficacy, the conservation of the entire trastuzumab molecule is required, suggesting involvement of an antibody-dependent cell-mediated cytotoxicity response and natural killer cell-mediated lysis [191].”
BackgroundNuclear Signaling by Receptor Tyrosine Kinases: The First Robin of Spring
Schlessinger, J., & Lemmon, M. A. (2006) · Cell · doi:10.1016/j.cell.2006.09.013 · Cited by 98 · cited 1×
“The biological consequences of this are unclear although the 80 kDa ICD may translocate to the nucleus where it may participate in transcriptional regulation [40,41].”
Background
Cited by
Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury
Bersell, K., Arab, S., Haring, B., & Kühn, B. (2009) · Cell · doi:10.1016/j.cell.2009.04.060 · Cited by 1,032
Rose, B. A., Force, T., & Wang, Y. (2010) · Physiological Reviews · doi:10.1152/physrev.00054.2009 · Cited by 723
Gao, R., & Penzes, P. (2015) · Current Molecular Medicine · doi:10.2174/1566524015666150303003028 · Cited by 516
“NRG-1 induces the phosphorylation of the ErbB4 receptors, which then become docking sites for upstream mTOR molecules such as PI3K [279].”
BackgroundRole of ErbB Receptors in Cancer Cell Migration and Invasion
Appert-Collin, A., Hubert, P., Crémel, G., & Bennasroune, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00283 · Cited by 310
Neuregulin in Cardiovascular Development and Disease
Odiete, O., Hill, M. F., & Sawyer, D. B. (2012) · Circulation Research · doi:10.1161/circresaha.112.267286 · Cited by 294
Metadata
- Authors
- Fuller, S. J., Sivarajah, K., & Sugden, P. H.
- Venue
- Journal of Molecular and Cellular Cardiology
- Publisher
- Elsevier BV
- Published
- 2008-05
- Volume
- 44
- Issue
- 5
- Pages
- 831-854
- ISSN
- 0022-2828 (ISSN-L)
- OpenAlex
- W2031944234
- Cited by
- 175
- References
- 15
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.